Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8.Ophthalmology. 1981;88(7):583–600.
2.
McDonaldHRSchatzH. Visual loss following panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology. 1985;92(3):388–393.
3.
BrownDMNguyenQDMarcusDM. Long-term outcomes of ranibizumab therapy for diabetic macular edema: The 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013; 120(10):2013–2022
4.
BrownDMSchmidt-ErfurthUDoDV. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID Studies. Ophthalmology. 2015;122(10):2044–2052.
5.
Writing Committee for the Diabetic Retinopathy Clinical Research Network; GrossJGGlassmanARJampolLM. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy A Randomized Clinical Trial. JAMA. 2015;314(20):2137–2146.
6.
ChewEYFerrisFLCsakyKG. The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study. Ophthalmology. 2003;110(9):1683–1689.
7.
LinJChangJSSmiddyWE. Cost evaluation of panretinal photocoagulation versus intravitreal ranibizumab for proliferative diabetic retinopathy. Ophthalmology. 2016;123(9):1912–1918.
8.
HuttonJSSteinJDBresslerNM. Cost-effectiveness of intravitreous ranibizumab compared with panretinal photocoagulation for proliferative diabetic retinopathy secondary analysis from a diabetic retinopathy clinical research network randomized clinical trial. JAMA Ophthalmol. 2017;135(6):576–584.
9.
ThompsonJTde BustrosSMichelsRG. Results and prognostic factors in vitrectomy for diabetic traction retinal detachment of the macula. Arch Ophth. 1987;105(4):497–502.
